The Prosigna test based on the PAM50 gene signature measures the expression of 50 genes in a surgically resected breast cancer sample to classify a tumor as one of 4 intrinsic subtypes (Luminal A, Luminal B, HER2-enriched [HER-2E], and basal-like). Here, ERBB2 is linked to breast carcinoma.